Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade.
Zheng J, Sha Y, Roof L, Foreman O, Lazarchick J, Venkta JK, Kozlowski C, Gasparetto C, Chao N, Ebens A, Hu J, Kang Y.
Zheng J, et al. Among authors: hu j.
Cancer Lett. 2019 Jan;440-441:1-10. doi: 10.1016/j.canlet.2018.10.003. Epub 2018 Oct 9.
Cancer Lett. 2019.
PMID: 30312729
Free PMC article.